21st Century Cures leaders vow to work out differences
This article was originally published in Scrip
The two members of the House who have been leading an effort to overhaul certain functions at the FDA and the National Institutes of Health and other areas of the US biomedical research and development enterprise wit the goal of accelerating the discovery, development and delivery of medical therapies have vowed to work out their differences and move the legislative process forward.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.